Synthesis process and technical content analysis of mivamutide injection

Mifamurtide injection (Mifamurtide) is an immunomodulatory drug mainly used to treat children and young adults (age less than 30 years old) with high-grade, non-metastatic osteosarcoma that has been completely removed by surgery. Its core active ingredient is a synthetic analog of a bacterial cell wall molecule whose structure mimics natural bacterial components (such as peptidoglycan fragments of the cell wall), which can effectively activate the innate immune system and induce the body to produce an immune clearance effect against tumors.

In terms of chemical synthesis, the synthesis process of mivamut peptide has a high technical content. Its active molecule is a sialic acid-peptide structure, which contains a key aminoacyl-formyl-glutamine (muramyl tripeptide) skeleton and is covalently linked to phospholiposomes to facilitate stable delivery to immune system-related cells. The synthesis process of this molecule involves multi-step protection-deprotection reactions, stereoselective amino acid coupling reactions and liposome encapsulation technology, and must be completed under a strict sterile environment and quality control system.

In addition, in order to improve its bioavailability, mivamut uses a liposome delivery system. This technology not only increases the stability of the drug in the blood, but also avoids premature degradation of the active substance. This liposome encapsulation method has excellent performance in terms of sustained release, safety and tissue targeting, reflecting the modernization and precision of the preparation process.

In general, mivamutin is not only a single small molecule drug, but also a high-tech immune activation platform product. This complex synthesis process also explains one of the reasons for its high production cost and high market price. At present, mivamutide has been approved for the treatment of osteosarcoma in Europe and the United States, and is considered to be one of the few immune auxiliary drugs that can prolong recurrence-free survival time and has significant clinical significance.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact